Hemostatic agents for prehospital hemorrhage control: a narrative review
HT Peng - Military Medical Research, 2020 - Springer
Hemorrhage is the leading cause of preventable death in combat trauma and the secondary
cause of death in civilian trauma. A significant number of deaths due to hemorrhage occur …
cause of death in civilian trauma. A significant number of deaths due to hemorrhage occur …
Hemostatic biomaterials to halt non-compressible hemorrhage
Non-compressible hemorrhage is an unmet clinical challenge, which occurs in inaccessible
sites in the body where compression cannot be applied to stop bleeding. Current treatments …
sites in the body where compression cannot be applied to stop bleeding. Current treatments …
Platelet-mimicking procoagulant nanoparticles augment hemostasis in animal models of bleeding
Treatment of bleeding disorders using transfusion of donor-derived platelets faces logistical
challenges due to their limited availability, high risk of contamination, and short (5 to 7 days) …
challenges due to their limited availability, high risk of contamination, and short (5 to 7 days) …
Prehospital lyophilized plasma transfusion for trauma-induced coagulopathy in patients at risk for hemorrhagic shock: a randomized clinical trial
D Jost, S Lemoine, F Lemoine, C Derkenne… - JAMA Network …, 2022 - jamanetwork.com
Importance Blood transfusion is a mainstay of therapy for trauma-induced coagulopathy, but
the optimal modalities for plasma transfusion in the prehospital setting remain to be defined …
the optimal modalities for plasma transfusion in the prehospital setting remain to be defined …
Hemostatic nanotechnologies for external and internal hemorrhage management
An uncontrolled hemorrhage can easily lead to death during surgery and military operations.
Despite the significant advances in hemostatic research, there is still an urgent and …
Despite the significant advances in hemostatic research, there is still an urgent and …
[HTML][HTML] Platelet‐inspired nanomedicine in hemostasis thrombosis and thromboinflammation
Platelets are anucleate cell‐fragments derived predominantly from megakaryocytes in the
bone marrow and released in the blood circulation, with a normal count of 150 000–40 000 …
bone marrow and released in the blood circulation, with a normal count of 150 000–40 000 …
Cargo-free particles divert neutrophil-platelet aggregates to reduce thromboinflammation
AL Banka, MV Guevara, ER Brannon… - Nature …, 2023 - nature.com
The combination of inflammation and thrombosis is a hallmark of many cardiovascular
diseases. Under such conditions, platelets are recruited to an area of inflammation by …
diseases. Under such conditions, platelets are recruited to an area of inflammation by …
[HTML][HTML] Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy
M Sun, MHH Pontius, S Yang, T Pendekanti… - Journal of Thrombosis …, 2023 - Elsevier
Background Fibrin-rich clot formation in thrombo-occlusive pathologies is currently treated
by systemic administration of plasminogen activators (eg tPA), to convert fibrin-associated …
by systemic administration of plasminogen activators (eg tPA), to convert fibrin-associated …
Topical hemostatic materials for coagulopathy
Medical science has witnessed significant progress in the development of hemostatic
materials, which save lives by supporting natural hemostatic ability. However, for the …
materials, which save lives by supporting natural hemostatic ability. However, for the …
Bioinspired artificial platelets: past, present and future
Platelets are anucleate blood cells produced from megakaryocytes predominantly in the
bone marrow and released into blood circulation at a healthy count of 150,000–400, 00 per …
bone marrow and released into blood circulation at a healthy count of 150,000–400, 00 per …